晚期胃癌化疗及分子靶向治疗研究进展

被引：24

作者：

王芳 ^{[1
]}

柳江 ^{[1
]}

罗健 ^{[1
,2
]}

机构：

[1] 乌鲁木齐, 新疆维吾尔自治区人民医院肿瘤科

[2] 北京, 中国医学科学院北京协和医学院肿瘤医院, 国家癌症中心肿瘤内科

来源：

中国医师杂志 | 2016年 / 18卷 / 01期

关键词：

胃肿瘤/治疗; 综述;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

目前化疗仍然是晚期胃癌的主要治疗手段, 但尚无标准方案。与最佳支持治疗相比, 化疗可延长患者中位生存期, 提高其生存质量。近年来, 随着各种新型抗癌药物的出现, 化疗方案不断演进, 晚期胃癌的治疗有效率和生存期得到进一步提高。同时, 随着胃癌分子生物学研究的不断深入, 针对人表皮生长因子受体2(HER-2)、表皮生长因子受体(EGFR)、血管内皮生长因子(VEGF)的分子靶向治疗成为胃癌综合治疗的热点。化疗联合分子靶向治疗在晚期胃癌中显示出良好的治疗效果及前景, 但仍需在临床研究和实践中进一步调整和优化。本文将结合最新文献, 对晚期胃癌的化疗及分子靶向治疗进行综述。

引用

共 13 条

[1]

REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis. [J].

Fuchs, Charles S. ;

Tomasek, Jiri ;

Cho, Jae Yong ;

Tomasello, Gianluca ;

Goswami, Chanchal ;

dos Santos, Lucas Vieira ;

Aprile, Giuseppe ;

Ferry, David ;

Melichar, Bohuslav ;

Tehfe, Mustapha Ali ;

Tehfe, All ;

Topuzov, Eldar ;

Zalcberg, John Raymond ;

Chau, Ian ;

Tabernero, Josep ;

Hsu, Yanzhi ;

Schwartz, Jonathan D. ;

Koshiji, Minori ;

Safran, Howard .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[2]

RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors. [J].

Wilke, Hansjochen ;

Van Cutsem, Eric ;

Oh, Sang Cheul ;

Bodoky, Gyorgy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg N. ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Emig, Michael ;

Carlesi, Roberto ;

Chandrawansa, Kumari ;

Muro, Kei ;

Ohtsu, Atsushi .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[3]

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. [J].

Al-Batran, Salah-Eddin ;

Van Cutsem, Eric ;

Oh, Sang Cheul ;

Bodoky, Gyorgy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg N. ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Muro, Kei ;

Liepa, Astra M. ;

Ballal, Shaila ;

Emig, Michael ;

Ohtsu, Atsushi ;

Wilke, Hansjochen .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[4]

A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005). [J].

Ramanathan, Ramesh K. ;

McDonough, Shannon L. ;

Kennecke, Hagen F. ;

Iqbal, Syma ;

Baranda, Joaquina Celebre ;

Seery, Tara Elisabeth ;

Lim, Howard John ;

Hezel, Aram F. ;

Vaccaro, Gina M. ;

Blanke, Charles David .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[5]

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP. [J].

Kawase, Tomono ;

Imamura, Hiroshi ;

Gotoh, Masahiro ;

Kimura, Yutaka ;

Ueda, Shugo ;

Matsuyama, Jin ;

Nishikawa, Kazuhiro ;

Sugimoto, Naotoshi ;

Fujita, Junya ;

Tamura, Takao ;

Fukushima, Norimasa ;

Kawabata, Ryohei ;

Kurokawa, Yukinori ;

Shimokawa, Toshio ;

Sakai, Daisuke ;

Tsujinaka, Toshimasa ;

Furukawa, Hiroshi .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[6]

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study [J].

Ohtsu, Atsushi ;

Ajani, Jaffer A. ;

Bai, Yu-Xian ;

Bang, Yung-Jue ;

Chung, Hyun-Cheol ;

Pan, Hong-Ming ;

Sahmoud, Tarek ;

Shen, Lin ;

Yeh, Kun-Huei ;

Chin, Keisho ;

Muro, Kei ;

Kim, Yeul Hong ;

Ferry, David ;

Tebbutt, Niall C. ;

Al-Batran, Salah-Eddin ;

Smith, Heind ;

Costantini, Chiara ;

Rizvi, Syed ;

Lebwohl, David ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) :3935-+

[7]

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial [J].

Li, Jin ;

Qin, Shukui ;

Xu, Jianming ;

Guo, Weijian ;

Xiong, Jianping ;

Bai, Yuxian ;

Sun, Guoping ;

Yang, Yan ;

Wang, Liwei ;

Xu, Nong ;

Cheng, Ying ;

Wang, Zhehai ;

Zheng, Leizhen ;

Tao, Min ;

Zhu, Xiaodong ;

Ji, Dongmei ;

Liu, Xin ;

Yu, Hao .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3219-+

[8]

Docetaxel and Cisplatin Plus Fluorouracil Compared With Modified Docetaxel, Cisplatin, and 5-Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Retrospective Analysis of Single Institution [J].

Inal, A. ;

Kaplan, M. A. ;

Kucukoner, M. ;

Isikdogan, A. .

NEOPLASMA, 2012, 59 (02) :233-236

[9]

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].

Ohtsu, Atsushi ;

Shah, Manish A. ;

Van Cutsem, Eric ;

Rha, Sun Young ;

Sawaki, Akira ;

Park, Sook Ryun ;

Lim, Ho Yeong ;

Yamada, Yasuhide ;

Wu, Jian ;

Langer, Bernd ;

Starnawski, Michal ;

Kang, Yoon-Koo .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) :3968-3976

[10]

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer [J].

Lim, Taekyu ;

Lee, Jeeyun ;

Lee, Duk Joo ;

Lee, Ha Yeon ;

Han, Boram ;

Baek, Kyung Kee ;

Ahn, Hee Kyung ;

Lee, Su Jin ;

Park, Se Hoon ;

Park, Joon Oh ;

Park, Young Suk ;

Lim, Ho Yeong ;

Kim, Kyoung-Mee ;

Kang, Won Ki .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) :255-262

← 1 2 →